Article Text

Download PDFPDF
Extended report
Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis
  1. Anastasia Papadopoulou1,2,
  2. Minas Yiangou2,
  3. Evangelia Athanasiou1,
  4. Nikolaos Zogas1,2,
  5. Panayotis Kaloyannidis1,
  6. Ioannis Batsis1,
  7. Athanasios Fassas1,
  8. Achilles Anagnostopoulos1,
  9. Evangelia Yannaki1
  1. 1Gene and Cell Therapy Center, Hematology Department–BMT Unit, George Papanicolaou Hospital, Thessaloniki, Greece
  2. 2Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University, Thessaloniki, Greece
  1. Correspondence to Evangelia Yannaki, George Papanicolaou Hospital, Gene and Cell Therapy Center, Hematology Department–BMT Unit, Thessaloniki 57010, Greece; eyannaki{at}


Objective The role of mesenchymal stem cells (MSC) in experimental arthritis is undoubtedly conflicting. This study explored the effect of bone marrow-derived MSC in previously untested and pathogenetically different models of rheumatoid arthritis (RA).

Methods MSC were tested both in an induced (adjuvant-induced) and a spontaneous (K/BxN) arthritis model. Arthritis was assessed clinically and histologically. The proliferation of splenocytes and fibroblast-like synoviocytes (FLS) in the presence of MSC was measured by radioactivity incorporation. Toll-like receptor (TLR) expression was measured by real-time PCR. T-regulatory cell (Treg) frequency, T-cell apoptosis and cytokine secretion were monitored by flow cytometry.

Results MSC, in vitro, strongly inhibited critical cell populations; splenocytes and FLS. In contrast, MSC proved ineffective in vivo, unless they were administered before disease onset, an effect implying that the inflammatory arthritic milieu potentially abrogates MSC immunomodulatory properties. In order to alleviate inflammation before MSC infusion, the authors administered, at arthritis onset, a short course with a proteasome inhibitor, bortezomib, whereas MSC were infused when established disease was expected. The bortezomib plus MSC group demonstrated a significantly decreased arthritis score over arthritic, MSC-only, bortezomib-only groups, also confirmed by histology and immunohistochemistry. The bortezomib plus MSC combination restored TLR expression and Treg frequency in blood and normalised FLS and splenocyte proliferation, apoptosis and cytokine secretion.

Conclusion MSC lose their immunomodulatory properties when infused in the inflammatory micromilieu of autoimmune arthritis. Conditioning of the recipient with bortezomib alters the disease microenvironment enabling MSC to modulate arthritis. Should milieu limitations also operate in human disease, this approach could serve as a strategy to treat RA by MSC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding Institutional funding was provided by G. Papanicolaou Hospital.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.